SAN DIEGO - Regulus Therapeutics Inc . (NASDAQ:RGLS), a biopharmaceutical company currently trading at $1.17 per share, today announced significant clinical and regulatory advancements in its ...
Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, is pleased to invite investors to a webinar on February 5 ...